For heart failure (CHF) and diabetes (DM) patients, a 15.3% decline in inpatient events was seen in the first twelve months following implementation of the CCS Advantage?„? disease management program (over the preceding twelve-month period); and For coronary artery disease (CAD) patients (a program introduced January 1st, 2008), a 20.9% decline in inpatient events was seen in the first three quarters of 2008 (over the same period in 2007). Similarly positive result patterns were noted in the examination of full-year (i.e., 12 month) periods and partial (i.e., nine month) year-over-year periods in all diseases managed with positive time dose dependence trends suggesting continued expansion of improvement in the setting of longer program engagement and involvement.

EmblemHealth supports its practitioners in the care and wellbeing of its members in a number of ways and we always seek programs that embrace measurement and a commitment to external validation of methods, said Dr. William Gillespie, SVP and Chief Medical Officer of EmblemHealth. We are firmly committed to continuously improving the quality and cost-effectiveness of care delivered to our Medicare beneficiaries and we are pleased with the results of our working together with MedAssurant.

CCS Advantage?„? is a unique solution to the problems of care management with respect to quality, outcomes, and costs notes Cary Sennett, MD, PhD, Chief Medical Officer of MedAssurant. CCS Advantage?„? combines MedAssurant ™s advanced analytics - which provide uniquely granular and detailed insights into the facts of each patient ™s case - with MedAssurant ™s broad outreach, touch, and response infrastructure. Combining this patient-specific, personalized approach with an ability to cover the patient ™s needs in print, by telephone, and in-market makes a material difference. The results show in patients ™ comments, outcomes, and cost savings.

medassurant/